AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?

At ASCO 2026, AstraZeneca will release the first results from its first-in-human, open-label Phase I/II trial, PRIMAVERA (NCT06137144). However, even with encouraging efficacy data, penetrating the Hodgkin lymphoma market is challenging. The trial introduces the first-in-class drug AZD3470, a selective PRMT5 inhibitor blocking arginine dimethylation for the treatment of haematological malignancies. Credit: Saiful52 via Shutterstock.com. On 30 May, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, AstraZeneca will release the first results from its first-in-human, modular, open-label Phase I/II trial, PRIMAVERA (NCT06137144). This introduces the first-in-class drug AZD3470, a selective PRMT5 inhibitor blocking arginine dimethylation…

Source: Clinical Trials Arena